October 05, 2022 at 8:33 pm

Soligenix Featured in Seeking Alpha as “Strong Buy”

With a “strong buy” recommendation, Soligenix (Nasdaq: SNGX) enjoyed a notable feature today in Seeking Alpha, a site that empowers investors “to make the absolute best investing decisions by leveraging our independent and balanced stock research, fundamental analysis tools, crowdsourced debate, reliable news and actionable market data.” The late-stage biopharma, now trading at a $20… [Read More]
October 05, 2022 at 1:35 am

Applied DNA (APDN) Skyrockets 36% on Market Rebound

Applied DNA (APDN) skyrocketed 36% today, taking advantage of the market rebound. APDN has been in the news lately with their launch of the Monkeypox testing service. “We believe we can play a key role in increasing rapid turn-around-time (“TAT”) monkeypox testing capacity to support healthier communities in our operating area of Long Island and… [Read More]
October 04, 2022 at 6:48 pm

NovaBay’s DERMADoctors Products Introduced to Millions of Households in QVC® Placement

Biopharmaceutical skincare company, NovaBay Pharmaceuticals (NYSE American: NBY) has made its third appearance on vCommerce leader, QVC. NovaBay Chief Product Officer, Dr. Audrey Kunin, joined Girls Night In with Courtney & Jane to introduce DERMADoctor’s Calm Cool + Corrected eczema and dermatitis clinical repair balm to millions of households across the United States. The segment… [Read More]
October 04, 2022 at 1:31 pm

DesCrypto Increases Foothold in Digital Collectibles Market with Penn State Collective Partnership

DesCrypto Holdings (OTC: DSRO) continues to strengthen its position in the sports and entertainment non-fungible token (NFT) industry. The company’s latest partnership, with Success with Honor, a non-profit organization, will allow Penn State fans to connect with student-athletes using Web3 and blockchain technology to deliver exclusive physical collectibles, utility, perks and in person experiences.  … [Read More]
September 29, 2022 at 10:13 pm

Sientra (SIEN) Shoots Up 21% Despite Rough Market Conditions

Sientra (SIEN) shot up 21% today, despite the market sell-off. It’s unclear why SIEN had such a great day. The Company’s latest press release is from last week where the Company announced that they have received regulatory approval to market breast implants in Saudi Arabia. Sientra offers innovative solutions and products around breast implants and… [Read More]
September 28, 2022 at 2:37 am

CytoSorbents (CTSO) Rises Almost 16% As They Receive Certification for Manufacturing

CytoSorbents (CTSO) shot up almost 16% as they announced that they just received ISO 13485 certification for its manufacturing facility in New Jersey. This achievement paves the way  for full manufacturing of CytoSorb®, DrugSorb®-ATR, and ECOS-300CY® from this site, with capacity to add additional product lines as they are developed. Mr. Vincent Capponi, President and Chief… [Read More]
September 23, 2022 at 12:05 pm

Soligenix’s Thermostable Filovirus Vaccine Program Has Potential For Global Impact

Company’s ThermoVax® platform has demonstrated protection against potentially lethal Ebola viruses Soligenix, Inc. (Nasdaq: SNGX), a late-stage biopharma company focused on developing and commercializing products to treat rare diseases continues work on its vital vaccine development program as a new outbreak of Sudan ebolavirus is declared in Uganda. While there is a vaccine for Zaire… [Read More]
September 21, 2022 at 10:32 pm

Adamis Pharma (ADMP) Plunges 28% As Covid Drug Candidate Shows No Efficacy

Adamis Pharma (ADMP) fell 28% on news of their clinical trial. Adamis released interim analysis of their Phase 2/3 trial of Tempol in high-risk subjects with Covid-19. The trial did not meet its primary endpoint, and based on the recommendation from the DSMB, the Company has halted the trial. “We are obviously disappointed that the… [Read More]
electronic blood pressure meter and red heart
September 21, 2022 at 9:52 am

Lexaria Bioscience: Taking Aim at the $28 Billion Hypertension Market; Human Clinical Study Yields “Remarkable” Results

Lexaria Bioscience (Nasdaq: LEXX) (Nasdaq: LEXXW) is targeting the $28 billion hypertension drug market with its innovative drug delivery platform. Its proprietary therapeutic, DehydraTECH-CBD, offers an alternative to traditional cannabidiol (CBD) dosing methods, enabling improved and more rapid absorption of drugs into the bloodstream and brain. There is currently only one FDA approved CBD drug… [Read More]